Navigation Links
Ceregene Announces Two Key Additions to Leadership Team

SAN DIEGO, April 23 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today announced that it has added two key people to its management team. Maurice Mezzino has been hired to the position of vice president, chief business officer, and Andrea Loewen-Rodriguez joins the company as senior director, regulatory affairs. These positions have been created to support development and commercial activities as Ceregene transitions to a later stage biotechnology company with two product candidates in clinical trials -- CERE-110 for Alzheimer's disease and CERE-120 for Parkinson's disease.

"We are excited to add two such experienced professionals to our leadership team during a time when we are advancing our product candidates into late-stage clinical development, with CERE-120 for Parkinson's disease potentially entering Phase 3 clinical trials next year," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer. "Maurice will be a key contributor toward our business and partnering strategies having structured and completed multiple deals during his career, and Andrea will play an important role in liaising with the FDA and European regulators in our efforts to move our therapies through the approval process."

Maurice Mezzino, a business development executive with more than 20 years of biopharmaceutical industry experience, joins us from Biogen Idec, where he has been since 2000, serving most recently as vice president, business development, responsible for managing the west coast business development team. Among his accomplishments, Mr. Mezzino spearheaded an oncology strategic alliance between IDEC and Biogen in 2003, which was a precursor to the merger between the companies later that year; and in 2006 he led the acquisition of Conforma Therapeutics. Prior to Biogen Idec, Mr. Mezzino held a variety of positions in clinical development, business planning, strategic marketing and business development at Bristol-Myers Squibb Company, Schering-Plough Corporation, Hoechst-Roussel Pharmaceuticals and Ayerst Laboratories. Maurice received a BA degree in environmental biology from Rutgers University, an MS degree in microbiology from Louisiana State University and an MBA in finance from Fairleigh Dickinson University. He is also a Chartered Financial Analyst (CFA).

Andrea Loewen-Rodriguez, a regulatory affairs professional with more than 18 years of biopharmaceutical industry experience, joins us from the regulatory affairs division at Biogen Idec, where she has been since 2000. Her responsibilities included developing and implementing global regulatory strategies and submissions for multiple products in clinical development. Prior to Biogen Idec, Ms. Loewen-Rodriguez held various positions with Nexell Therapeutics and Baxter Healthcare Corp. Andrea holds a Regulatory Affairs Certification and received her BA degree in biology from Gustavus Adolphus College.

About Ceregene

Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth factors for the treatment of neurodegenerative disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in Phase 1 studies for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) which has completed enrollment of a controlled Phase 2 study for Parkinson's disease. CERE-135 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, Inc. (Nasdaq: CEGE) as well as Hamilton BioVentures and California Technology Partners.

SOURCE Ceregene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
2. Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call
3. Warner Chilcott Announces Earnings Release Date and Conference Call for First Quarter 2008 Financial Results
4. Webcast Alert: Transgenomic Inc. Announces First Quarter 2008 Earnings Release Conference Call Webcast
5. Rochester Medical Announces Second Quarter 2008 Earnings Conference Call April 29, 2008
6. BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock
7. UltraTape Announces Sample Kits Available for Purchase Through Website
8. IMPAC Medical Systems Announces 2008 Laboratory Professionals of the Year
9. Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection
10. Fufeng Announces 2007 Annual Results
11. Pharmacyclics Announces It Received Nasdaq Notification
Post Your Comments:
(Date:10/12/2015)... , Oct. 12, 2015  Patara Pharma, ... allergic and inflammatory diseases and conditions, today announced ... preferred stock financing. Concurrent with the close of ... into a Loan and Security Agreement with Silicon ... to $7 million. Patara will use the funds ...
(Date:10/12/2015)... NAMUR , Belgium , Oct. 12, ... today announced that full results from a completed clinical study ... pancreatic cancers have been published in the online issue of ... Epigenetics Society. The peer-reviewed study was conducted in collaboration with ... , and led by Roland Andersson , MD, PhD, ...
(Date:10/12/2015)... ... 2015 , ... LifeTrak , a leader in consumer fitness, heart rate ... amphibious fitness tracker that seeks to meet the needs of multi-sport athletes. Zoom is ... monitoring both in water and on land, making it the only fitness tracker ...
(Date:10/10/2015)... ANNAPOLIS, Maryland , 10. Oktober, 2015 /PRNewswire/ ... O. Matsui (Abgeordnete der Demokratischen Partei für Kalifornien) ... 11. bis 17. Oktober) in die Aufzeichnungen des ... Plasma Protein Therapeutics Association (PPTA) und ... , Hebung des Bewusstseins über Plasmaspenden ...
Breaking Biology Technology:
(Date:10/12/2015)... , Oct. 9, 2015 Research and Markets ... Research, Inc,s new report "Biometrics: Market Shares, Strategies, ... --> --> The ... the Biometrics market segment. Research represents a selection from ... and cogent market materials, with selections made by the ...
(Date:10/12/2015)... -- Research and Markets ( ) has ... Market by Component (Hardware & Software), Product (Scanner ... (Travel & Immigration, Military & Defense, & Others) ... report to their offering. ... worth 3627.90 Million USD by 2020 ...
(Date:10/8/2015)... Oktober 2015 Die Track Group, ... des Bereiches Tracking, hat heute bekannt gegeben, ... Virginias (Department of Corrections – DOC) unterzeichnet ... alle Strafen geliefert werden, die der Behörde ... für den Amerikanischen Kontinent der Track Group. ...
Breaking Biology News(10 mins):